Pipeline
With our Aonys drug delivery platform and our network of experts, we are preparing numerous developments of new drugs with buccal administration and intracellular delivery of various water-soluble active ingredients.
Our goal is to provide innovative solutions in major therapeutic areas, currently lacking efficacy treatments.
| Product | Preclinical | Phase 1 | Phase 2 | Phase 3 | Property / Partner | |||
|---|---|---|---|---|---|---|---|---|
| NEURODEGENERATIVE DISEASES | ||||||||
| NanoLithium Alzheimer’s disease | 100 | 100 | 50 | 0 |  |
|||
| NanoLithium Huntington’s disease | 100 | 100 | 0 | 0 | |
|||
| NanosiRNA Huntington’s disease | 100 | 0 | 0 | 0 | |
|||
| NanoP42T Huntington’s disease | 100 | 0 | 0 | 0 | |
|||
| ONCOLOGY | ||||||||
| NanosiRNA IFNAR | 100 | 0 | 0 | 0 |  |
|||
| NanoManganeseRadiotherapy Glioblastoma | 100 | 0 | 0 | 0 | |
|||
| NUCLEAR DRUGS | ||||||||
| NU01 Plutonium decorporation | 100 | 0 | 0 | 0 | |
|||
| NU02 Cesium decorporation | 100 | 0 | 0 | 0 | |
|||
| NanoMn Radioprotection | 100 | 100 | 0 | 0 | |
|||